CA2496938A1 - Compositions et procedes d'utilisation de peptides de ciblage concus pour le diagnostic et le traitement du cancer humain - Google Patents
Compositions et procedes d'utilisation de peptides de ciblage concus pour le diagnostic et le traitement du cancer humain Download PDFInfo
- Publication number
- CA2496938A1 CA2496938A1 CA002496938A CA2496938A CA2496938A1 CA 2496938 A1 CA2496938 A1 CA 2496938A1 CA 002496938 A CA002496938 A CA 002496938A CA 2496938 A CA2496938 A CA 2496938A CA 2496938 A1 CA2496938 A1 CA 2496938A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- peptide
- phage
- targeting
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des compositions et des procédés d'identification et d'utilisation de peptides de ciblage sélectifs pour les tissus cancéreux, en particulier de la prostate ou de l'ovaire. Le procédé peut consister à identifier des mimotopes endogènes de ces peptides, tels que GRP78, IL-11R.alpha. et hsp90. Des anticorps contre ces peptides de ciblage ou leurs mimotopes peuvent servir à la détection, au diagnostic et/ou à la stadification du cancer de la prostate ou de l'ovaire. Dans d'autres modes de réalisation, les compositions et procédés portent sur un nouveau type de vecteur de thérapie génique, appelé phage associé aux adénovirus (AAP). Les AAP conviennent pour l'administration ciblée d'agents thérapeutiques à des tissus, des organes ou des types cellulaires particuliers, par exemple les cancers de la prostate ou de l'ovaire. Dans d'autres modes de réalisation encore, les peptides de ciblage sélectifs pour des lipomes bénins peuvent faciliter la détection, le diagnostic et l'administration ciblée d'agents thérapeutiques.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US02/27836 | 2002-08-30 | ||
PCT/US2002/027836 WO2003022991A2 (fr) | 2001-09-07 | 2002-08-30 | Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires |
PCT/US2002/034987 WO2004020999A1 (fr) | 2002-08-30 | 2002-10-30 | Compositions et procedes d'utilisation de peptides de ciblage conçus pour le diagnostic et le traitement du cancer humain |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2496938A1 true CA2496938A1 (fr) | 2004-03-11 |
Family
ID=31975571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002496938A Abandoned CA2496938A1 (fr) | 2002-08-30 | 2002-10-30 | Compositions et procedes d'utilisation de peptides de ciblage concus pour le diagnostic et le traitement du cancer humain |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1546714A4 (fr) |
AU (1) | AU2002364501A1 (fr) |
CA (1) | CA2496938A1 (fr) |
WO (1) | WO2004020999A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1521776A2 (fr) | 2002-07-04 | 2005-04-13 | Oncomab Gmbh | Anticorps specifiques de neoplasme et utilisations associees |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
EP1531162A1 (fr) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
US20050191294A1 (en) * | 2003-12-31 | 2005-09-01 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
BRPI0710671B8 (pt) * | 2006-04-07 | 2021-05-25 | Univ Texas | uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa |
JP5374360B2 (ja) * | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | 抗grp78抗体を有効成分として含む医薬組成物 |
US20110189095A1 (en) * | 2008-06-20 | 2011-08-04 | The Board Of Regents, Of The University Of Texas System | Crkl targeting peptides |
CN102120755B (zh) * | 2010-04-23 | 2013-04-03 | 江苏省人民医院 | 一种棕色脂肪组织靶向性多肽及其应用 |
CN113278731A (zh) * | 2021-05-12 | 2021-08-20 | 广西医科大学 | 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) * | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
ATE229073T1 (de) * | 1996-09-06 | 2002-12-15 | Univ California | Protein e25a, methoden zu dessen herstellung und anwendung |
US6261789B1 (en) * | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Methods for detecting the presence of a PSCA protein using PSCA antibodies |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
ATE478141T1 (de) * | 2000-09-08 | 2010-09-15 | Univ Texas | Durch phagendisplay identifizierte zielpeptide des menschen und der maus |
AU2001288914A1 (en) * | 2000-09-08 | 2002-03-22 | Board Of Regents, The University Of Texas System | Biopanning and rapid analysis of selective interactive ligands (brasil) |
-
2002
- 2002-10-30 CA CA002496938A patent/CA2496938A1/fr not_active Abandoned
- 2002-10-30 WO PCT/US2002/034987 patent/WO2004020999A1/fr not_active Application Discontinuation
- 2002-10-30 EP EP02799873A patent/EP1546714A4/fr not_active Withdrawn
- 2002-10-30 AU AU2002364501A patent/AU2002364501A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1546714A4 (fr) | 2007-12-05 |
EP1546714A1 (fr) | 2005-06-29 |
WO2004020999A1 (fr) | 2004-03-11 |
AU2002364501A1 (en) | 2004-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7671010B2 (en) | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer | |
US8507445B2 (en) | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer | |
US8710017B2 (en) | Human and mouse targeting peptides identified by phage display | |
EP1322755B1 (fr) | Peptides de ciblage humains et murins identifies par expression phagique | |
US8846859B2 (en) | Compositions and methods of use of targeting peptides against placenta and adipose tissues | |
AU2010249304B2 (en) | Human and mouse targeting peptides identified by phage display | |
US20040048243A1 (en) | Methods and compositions for in vitro targeting | |
CA2496938A1 (fr) | Compositions et procedes d'utilisation de peptides de ciblage concus pour le diagnostic et le traitement du cancer humain | |
EP1497314A2 (fr) | Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires | |
Class et al. | Patent application title: COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES FOR DIAGNOSIS AND THERAPY OF HUMAN CANCER Inventors: Wadih Arap (Houston, TX, US) Mikhail G. Kolonin (Houston, TX, US) Mikhail G. Kolonin (Houston, TX, US) Paul J. Mintz (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Amado J. Zurita (Houston, TX, US) | |
CA2730627C (fr) | Peptides de ciblage humains et murins identifies par expression phagique | |
Class et al. | Patent application title: HUMAN AND MOUSE TARGETING PEPTIDES IDENTIFIED BY PHAGE DISPLAY Inventors: Wadih Arap (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Assignees: Board of Regents, The University of Texas System | |
Class et al. | Patent application title: COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES AGAINST PLACENTA AND ADIPOSE TISSUES Inventors: Renata Pasqualini (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Wadih Arap (Houston, TX, US) Mikhail G. Kolonin (Houston, TX, US) Mikhail G. Kolonin (Houston, TX, US) | |
AU2007203251A1 (en) | Compositions and methods for targeting peptides in humans in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |